Bevacizumab in HER2 Negative Metastatic Breast Cancer

Speaker: Christoph Zielinski

C.Zielinski comments on two milestone phase 3 trials, TANIA and IMELDA, analysing efficacy and safety of continuing vs stopping bevacizumab (bev) in HER2 neg MET breast cancer. He concludes these results are immediately impacting clinical practice since bev has shown an interesting advantage for these patients.

Discussion Points

  • Rationale for the IMELDA and TANIA studies
  • Top line results of both studies
  • What are the implications for clinical practice and warrants for further research

Abstracts Discussed